(Q36641336)

15 August 2017

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs (English)

1 reference

15 August 2017

1 reference

1 reference

Screnci D

1

1 reference

15 August 2017

McKeage MJ

2

1 reference

15 August 2017

Galettis P

3

1 reference

15 August 2017

Hambley TW

4

1 reference

15 August 2017

Palmer BD

5

1 reference

15 August 2017

Baguley BC

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

82

1 reference

15 August 2017

4

1 reference

15 August 2017

966-972

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1026

15 August 2017

0 references

cites work

Testicular cancer: an oncological success story

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Comparative adverse effect profiles of platinum drugs.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Carboplatin: the clinical spectrum to date

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374394

Protein binding of five platinum compounds. Comparison of two ultrafiltration systems

20 September 2018

1 reference

12 December 2020

Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships

1 reference

12 December 2020

Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat

1 reference

12 December 2020

Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)

1 reference

12 December 2020

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

12 December 2020

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation

1 reference

12 December 2020

Chemotherapy of advanced ovarian cancer

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.1999.1026

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference